USPTO serial 79348594
VIVIBEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 2, 2025
- Examiner
- COUGHLAN, REBECCA D.
- Law office
- GENERIC WEB UPDATE
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with VIVIBEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Keith A. Weltsch
Keith A. Weltsch Scully, Scott, Murphy & Presser, P.C.400 Garden City PlazaSuite 300Garden City, NY 11530Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical additives for use in the manufacture of food products; vitamins for use in the manufacture of food products; chemical additives for use in the manufacture of food as enrichment of food composition; vitamins for use in the manufacture of food as enrichment of food composition; chemical products, namely, chemical additives to be used in the manufacture of food supplements; chemical products, namely, chemical additives to be used in the manufacture of pharmaceuticals and veterinary products; vitamins to be used in the manufacture of pharmaceutical and veterinary products; oleoylethanolamide to be used in the production of food and reinforced food; oleoylethanolamide to be used in the production of pharmaceutical and veterinary products; oleoylethanolamide to be used in the production of medical food; oleoylethanolamide to be used in the production of dietary ingredients in the nature of dietary supplements and food supplements; oleoylethanolamide and palmitoylethanolamide combination for use in the production of pharmaceutical and veterinary products; oleoylethanolamide and palmitoylethanolamide combination for use in the production of food and medical food; oleoylethanolamide and palmitoylethanolamide combination for use in the production of food supplements; oleoylethanolamide and palmitoylethanolamide combination used in the manufacture of dietary ingredients in the nature of dietary supplements; anandamide for use in the production of medical food; anandamide for use in the production of food supplements; anandamide for use in the production of pharmaceutical products; combination of oleoylethanolamide, palmitoylethanolamide, anandamide for use in the production of food, medical food, food supplements, dietary ingredients, pharmaceutical and veterinary products; anandamide with purity from 10 percent to 99 percent for use in the production of food, medical food, food supplements, dietary ingredients, pharmaceutical and veterinary products; oleoylethanolamide with purity from 10 percent to 99 percent for use in the production of food, medical food, food supplements, dietary ingredients, pharmaceutical and veterinary products; spermidine, spermine, aliphatic polyamine used in the production of food and medical food; spermidine, spermine, aliphatic polyamine to be used in the production of pharmaceutical and veterinary products; spermidine, spermine, aliphatic polyamine used in the production of food supplements and dietary ingredients; spermidine, spermine, aliphatic polyamine used in the manufacture of food to reinforce or enrich food, food extract and fermented food; polyamines and acyl ethalonammides combination for use in the production of food, food supplements, pharmaceuticals, dietary products in the nature of dietary supplements; phosphatidylserine, phosphatidylcholine, phosphatidylethanolamine, phosphatidylenositol as single entity to be used in the manufacture of food, medical food, food supplements, pharmaceutical, veterinary products; natural phospholipids (PS, PC, PE, PI) and acyl ethanolammides combination in powder form and in oil dispersion or emulsion for use in the manufacture of medical food, food supplements; combination of natural phospholipids (PS, PC, PE,PI), spermidine, spermine in powder form and in oil dispersion or emulsion for use in the manufacture of medical food, food supplements; combination of natural phospholipids (PS, PC, PE, PI), L (-) methyl tetraidofolic acid or its salts in powder and fluid form for use in the manufacture of medical food, food supplements; natural lecithynes added with spermidine, spermine and other natural aliphnatic polyamines in powder and oil form for use in the manufacture of medical food, food supplements; natural lecithynes added with L (-) methyl tetraidofolic acid and or folic acid in powder and oil form for use in the manufacture of medical food, food supplements; any hemp in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing goods containing CBD | ACTIVE | — |
| 005 | Nutraceuticals for use in therapeutical diets, for the treatment of inflammation, cardiological conditions, diabetes, obesity or overweight people; nutraceuticals for use as dietary supplements; vitamin preparations; dietetic foods, namely, bakery goods adapted for medical purposes; wheat germ dietary supplements; dietary supplements for animals; food supplements containing folic acid, methyltetrahydrofolic acid, L (-) methyl tetraidofolic acid and its salts; nutraceutical preparations for medical purposes, to be used to improve the quality of life of oncological patients, namely, for the treatment of cancer; pharmaceutical products for use by human beings, namely, ocular pharmaceuticals; veterinary products, namely, dietary supplement nutraceuticals, amino acids and biological preparations for veterinary purposes for the treatment of cancer; dietetic foods adapted for medical use; dietary supplements for human beings and animals; dietary food supplements for medical use containing oleoylethanolamide, palmithoylethanolamide, anandamide, spermidine, spermine, phosphatidylserine, natural phospholipids, L (-) methyltetrahydrofolic acid and its salts, added or enriched with the above chemical nutrients to improve the nutritional value or the health benefits, eventually added with other products excipients, and processing aids used in human or animal diet; any hemp in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing goods containing CBD | ACTIVE | — |
| 029 | Animal fats for food; blended oil for food; soya milk; yogurt; breakfast yogurt; milk; cheese; fermented milk; goat milk; powdered milk; processed shell fruits; condensed milk; food products made from meat, fish, poultry and game, namely, meat-based snack foods, fish-based snack foods; food products made from fruits and vegetables, namely, dried fruits and vegetables, preserved fruits and vegetables, cooked fruits and vegetables; all of the foregoing goods featuring palmithoylethanolamide, oleoylethanolamide, anandamide, poliamines, namely, spermidine, spermine, phosphatidylserine, being added, alone and natural phospholipid in combination with the aforementioned goods; any hemp in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing goods containing CBD | ACTIVE | — |
| 030 | Chocolate; ice cream; biscuits; breakfast cereals; pizzas; bakery goods; rice; popcorn; soya flour; starch-based thickeners for whipped cream; flour; bread; pastries; frozen confectionery; fruit jellies being candies; baking powder; cooking salt; food products made from rice, flour and cereals, namely, rice, flour and processed cereals with added folic acid, methyltetrahydrofolic acid, L (-) methyltetrahydrofolic acid and its salts, and folic acid derivates; food products being pastry, petit fours and confectionery made of sugar; all of the foregoing goods featuring palmithoylethanolamide, oleoylethanolamide, anandamide, poliamines, namely, spermidine and spermine phosphatidylserine, being added, alone, and natural phospholipid in combination with the aforementioned goods; any hemp in the goods being solely derived from hemp with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing goods containing CB | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by FRAU PHARMA S.R.L.
- Other trademarks owned by FRAU PHARMA S.R.L.
- Other trademarks owned by FRAU PHARMA S.R.L.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 029
- Other trademarks in Class 030
- Similar marks named VIVIBEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 2, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 16, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 16, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 2, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 7, 2025 | CHPN | POST PUBLICATION AMENDMENT – NOT ENTERED | — |
| Oct 6, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| Sep 2, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 2, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 26, 2025 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jul 15, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 15, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 9, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 12, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 12, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 12, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 12, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 12, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 3, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 3, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 3, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 21, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 3, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 3, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 26, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 7, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 7, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 14, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 17, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 8, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 21, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 13, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 7, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 6, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Sep 1, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |